Mpathy Medical is touting the results of a small study of its Omnisure sling for treating female stress urinary incontinence.
The Glasgow, Scotland based company, which has its U.S. headquarters in Raynham, Mass., said the 61-patient trial showed a 92.4 percent cure rate, defined as patients who were reported as “dry” after implantation.
Pubovaginal slings are implanted under the neck of the bladder (the proximal or mid-urethra) to physically support them and relieve the stress that causes incontinence. Mpathy claims the Omnisure device can be implanted using the narrowest needle possible.
Mpathy entered the U.S market last year, after raising equity capital to fund the entry from Archangel Informal Investment and Scottish Enterprise.
A third financing round, completed earlier this year, brought the total amount invested in the company in the past year to more than $5.4 million.